Merck & Co. announced a multi‑year collaboration with Guardant Health to advance its oncology portfolio by integrating Guardant’s Infinity Smart liquid‑biopsy platform into drug development and commercialization efforts.
The partnership will focus on creating companion diagnostics and accelerating the launch of new cancer therapies, enabling Merck to identify patients most likely to benefit from its immuno‑oncology products, including the blockbuster drug Keytruda.
Guardant’s Infinity Smart platform delivers comprehensive molecular profiling from a single blood sample, providing real‑time monitoring of tumor evolution and guiding treatment decisions across multiple cancer types.
Merck’s oncology portfolio, which already includes Keytruda and other immuno‑oncology assets, will be strengthened by the collaboration, creating new revenue opportunities and reinforcing the company’s precision‑medicine positioning.
While the financial terms of the agreement were not disclosed, the multi‑year nature of the deal signals a long‑term commitment to integrating diagnostics with drug development and commercialization.
Helmy Eltoukhy, Guardant’s chairman and co‑CEO, said the collaboration “allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today,” underscoring the strategic fit between the two companies.
The announcement reflects Merck’s broader strategy to partner with technology firms to accelerate oncology pipeline development and improve patient outcomes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.